pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

95 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints630BioPharma Dive241onclive165Fierce Biotech92BioSpace91raps37globenewswire health28
therapy area
allOncology4988Rare Disease818Hematology759Cardiology716Immunology715Psychiatry & CNS579Pulmonology570Vaccines
  • Opinion: AI’s growing appetite for power is a public health issue. Here’s a fix
    “AI is creating a new and largely overlooked strain on something fundamental to health,” write Sten H. Vermund and Patricia J. Kissinger.
    STAT · 1mo ago↗ source
  • Covid vaccination cut risk of adverse heart events, large study finds
    Covid vaccination was also tied to a nearly 24% reduction in all-cause cardiac events in a large study, surprising researchers.
    STAT · 1mo ago↗ source
  • Opinion: ‘I’m pretty much all in’: An interview with a woman starting medical residency at almost 73
    "There are some physicians that work to 100”: Dawn Zuidgeest-Craft on becoming a medical doctor in her 70s.
    STAT · 1mo ago↗ source
← prev
page 3 of 4
next →
fda recalls22
fda press21
fda medwatch17
505
Endocrinology & Metabolism288
Ophthalmology254
Infectious Disease238
Nephrology227
  • Merck brings Welireg-Keytruda combo to treat kidney cancer
    Merck’s Welireg and Keytruda combination won approval as an adjuvant treatment for kidney cancer patients after surgery to remove all or part of the organ. The combination was approved Friday for ...
    Endpoints · 1mo ago↗ source
  • SonoThera raises $125M for non-viral gene therapy approach
    SonoThera has secured $125 million to take its ultrasound-based gene therapy technology into the clinic. The company is focused on two lead programs in Duchenne muscular dystrophy and autosomal dom…
    Endpoints · 1mo ago↗ source
  • AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
    Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell…
    BioPharma Dive · 1mo ago↗ source
  • Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough
    “Innovations like xenotransplantation would never have reached clinical trials without animal experimentation,” writes transplant surgeon Joshua Mezrich.
    STAT · 1mo ago↗ source
  • Opinion: $2 million gene therapy cures require a financing model
    “We do not lack cures. We lack the infrastructure to pay for and deliver them,” writes William Padula.
    STAT · 1mo ago↗ source
  • STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
    Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
    STAT · 1mo ago↗ source
  • STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
    Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
    STAT · 1mo ago↗ source
  • STAT+: Will Makary’s FDA voucher program survive?
    RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news
    STAT · 1mo ago↗ source
  • Texas AG investigating energy drinks
    The limitations of private health insurance, the quiet collapse of America's research ethics watchdog and other Morning Rounds news
    STAT · 1mo ago↗ source
  • HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy
    Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment.
    STAT · 1mo ago↗ source
  • STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program
    The White House has used the program to reward companies that help its political goals.
    STAT · 1mo ago↗ source
  • STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
    Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.
    STAT · 1mo ago↗ source
  • Otsuka showcases kidney drug data; Pfizer cuts an AI deal
    Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off gen…
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Legend Biotech emerged as a rare market winner
    New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
    Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup. Ascidian’s ...
    Endpoints · 1mo ago↗ source
  • Lilly, Ascidian link up in RNA exon editing pact
    Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
    Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • Travere pays Everest $112M upfront to grow rare kidney disease pipeline
    Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…
    Endpoints · 1mo ago↗ source
  • How one state’s medical meal program lowered health care costs
    Medicaid work requirements, fast-tracked funding for experimental Ebola vaccines, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Opinion: I’m a heart transplant recipient. I’m haunted by ‘ghost approval’ for medication I need to survive
    “On paper, I have insurance coverage. In real life, I don’t have access. That’s what I call ‘ghost approval,’” writes patient advocate Payton Herres.
    STAT · 2mo ago↗ source
  • FDA approves AstraZeneca’s new kind of hypertension drug
    Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.
    BioPharma Dive · 2mo ago↗ source
  • Opinion: Telehealth abortion with mifepristone continues, with backup plans still in place
    Restricting telehealth prescribing of mifepristone wouldn't spell the end of telehealth medication abortion, writes OB-GYN Christine Henneberg.
    STAT · 2mo ago↗ source